## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type I	Responses	)														
1. Name and Address of Reporting Person * Lin Patrick					2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106					3. Date of Earliest Transaction (Month/Day/Year) 12/31/2021							X Officer (give title below) Other (specify below)  Chief Business - Strategy Off				
(Street)					4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
HANOVER, MD 21076					rom med by more than one reporting reason											
(City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Dispos									Beneficially	Owned	
(Instr. 3) Date			*****	Execut any	a. Deemed secution Date, it y Jonth/Day/Year		(Instr.		(A) or	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Beneficia	lly Owned F Transaction	Owned Following ransaction(s)		7. Nature of Indirect Beneficial Ownership
				(IVIOIII			Code	· V	Amount (A) or (D) Price		Price					(Instr. 4)
Common Stock 12/14/2021			12/14/2021				P		3,000	) A	\$4	429,390			D	
Security (Instr. 3) Pri	2. 3. Transaction Date (Month/Day/ Security		3A. Deemed Execution Dat any	e.g., puts, calls, wa 4. te, if Transaction Code (Instr. 8)		rrants, o	the ired, Doptions 6. I and (Moves 8)	the form displays a curred, Disposed of, or Beneficiptions, convertible securitie  6. Date Exercisable and Expiration Date (Month/Day/Year)  e			ntly valid	8. Price of	9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	of 10. Owners Form of Derivat Security Direct ( or Indir	ive Ownersh y: (Instr. 4) D) ect	
					Code		(A) (E	Dat Exe	e rcisable	Expiration Date	n Title	Amount or Number of Shares				
Reporti	ng O	wners														
				Relationships												
Reporting Owner Name / Address					Director 10% Owner Of				Officer			Oth	er			
Lin Patrick C/O PROCESSA PHARMACEUTICALS, INC 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076					Chief Business - Strategy O						Off					
Signatu	res															

12/16/2021

Date

## **Explanation of Responses:**

/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact

\*\*Signature of Reporting Person

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.